Abstract
The US healthcare system involves a multitude of stakeholders; a mix of public
and private players. The government funds healthcare for certain sections of
the society while majority of the population has a private health insurance
sponsored by employers. Pharmaceutical manufacturers in the US are relatively
free to set their own prices for drugs which tend to be, on an average, two to
three times higher than in Europe. The US market in general works by
administering reimbursement controls rather than price controls. Instead of a
direct price control, the government is known to have been using tacit
persuasion tactics, on grounds of morality, to convince drug companies to
slash prices. However the scenario is changing in light of a growing demand
for administering direct price controls. The report provides analysis on the
performance of key brands in a range of major indications in the US
pharmaceutical market, including central nervous system disorders, cancer,
cardiovascular diseases and metabolic disorders. The report also incorporates
analysis of the portfolios and pipelines of the leading pharmaceutical
companies active in the US market today.
| 
View Cart
